People

The People

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Governance grade: C+. A founder who owns nearly half the equity and has put real money into a recovery, sitting on top of a thin independent layer, two unexplained mid-year board exits, an auditor resignation in August 2025, a dilutive warrant scheme that is now under water by 60%, and a sales-return episode in FY24 that exposed weak internal controls. Skin-in-the-game is genuine; the board's ability to challenge management is not.

1. The People Running This Company

The story is asymmetric: one founder with 48% economic interest carries the operating weight; the rest of the board is structurally light. Karlekar's appointment is the only addition that materially raises agrochem domain credibility. Two directors (BalavenkataRama Suryadevara and Shuvendu Satpathy) resigned together on 2 July 2025 with no public explanation — Suryadevara was an Executive WTD on $229K; Satpathy chaired the Stakeholders Relationship Committee and was paid $16K in unspecified "other" fees while sitting as a non-independent NED. The auditor (Walker Chandiok & Co LLP) resigned on 14 August 2025; new auditor was appointed 1 October 2025. Company Secretary Astha Wahi also resigned, replaced by Aarti Arora. Three governance touchstones — board, auditor, compliance officer — turned over inside one fiscal quarter.

2. What They Get Paid

*Resigned 2 July 2025.

Pay is modest in absolute terms — total board cash compensation is roughly $0.56M against $134M of revenue, and a founder-MD on $281K is not extracting an outsized rent. The structural problems sit elsewhere:

• Disclosure is minimal. The company invokes Section 136(1) to keep the Rule 5(2)/5(3) detailed remuneration table out of the public annual report. Members can write in for the full disclosure — a legal carve-out that hides what most peers publish freely.
• Pay is fixed, not earned. The MD's package is "Salary & Allowances" with reference to Section 197/Schedule V minimums. Performance-linked variable is mentioned in policy but not quantified; against a year that swung from $12.7M PAT (FY24) to $5.2M (FY25) with a Q4 FY24 $8.7M loss, pay barely flexed.
• Independent-director fees are skewed. The Audit Chair (Mrs. Chetna) attended every Audit, NRC, Stakeholders, Risk and CSR meeting — and received $1.8K in sitting fees, while the Chairman (Mr. Braj Kishore Prasad) received $15.2K for similar attendance. The Audit Chair carries the heaviest workload at the lowest compensation, the inverse of what a serious board does.
• A non-independent NED received $16K in "other" fees. Shuvendu Satpathy was non-executive and non-independent; the AR records his payment as "other" rather than sitting fees and offers no description of services rendered.

3. Are They Aligned?

Ownership

Insider activity & institutional flows

Promoter holding crept up 34 bps (from 50.10% to 50.44%) — small but directionally positive. The big move was on the institutional side: FII ownership halved from 10.84% in Q2 FY24 to 5.63% by FY26, a ~5 pp exit during the period the operating story unraveled. Mutual funds drifted down from 2.55% to 2.11%. The slack was absorbed by retail (public) holders, which rose from 36.5% to 41.8% — accumulation into a falling stock. Promoter pledge is 0% as of December 2025, confirmed by ET / NSE filings.

The transcript record is also revealing. On the Q3 FY26 call, an investor asked whether the 7–9% holder "Raj Kumar" (same first name as MD's surname Alawadhi/Kumar) is connected to the promoter group. Management's answer — "Not clear, we are not aware of Rajkumar… there is no relationship" — left the question unresolved despite Raj Kumar selling roughly $11.9M of stock in September 2022 around the company's split-and-bonus action. The disclosure is consistent with the formal record (he is not listed in promoter group) but the on-call exchange demonstrated minimal management curiosity about a 9% non-promoter holder.

Dilution and the warrant overhang

The Board approved 31,25,000 convertible warrants at $7.64 in September 2024; only 23,43,750 were allotted (the company says ₹7,81,250's worth of upfront 25% never landed, vague language for what was effectively a missed payment by a subset of allottees). After the equity split (face value 10:1) and bonus issue, the effective strike is ~$0.49; the share trades at ~$0.19. Allottees are deeply out of the money; the balance 75% is due by June 2026 and management on the Q3 FY26 call would not commit that the conversion will happen ("we are still waiting for our March numbers and then we will take a decision"). Against that, the planned CAPEX is on hold because it was contingent on the 75% balance arriving.

The 25% upfront proceeds — already used for working capital — gave the company near-term liquidity in exchange for an option that is now far out of the money. If allottees walk away, the upfront 25% is forfeited (a small windfall to the company) but the equity injection the balance sheet needed never arrives. The warrant scheme has effectively become an interest-free loan with no equity follow-through — a poor outcome relative to the stated purpose of "growth in business."

Related-party behavior, dividends, capital allocation

The annual report states no material related-party transactions exist; auditor's report is unqualified. The footnote, however, mentions a SOP penalty for delay in filing of RPT disclosure under SEBI LODR Reg 23(9) — disclosed as compliance trivia but worth noting. The company also has subsidiaries with overlapping directorships (Pramod Karlekar sits on Best Crop Science Pvt Ltd, the largest WoS) where investors must rely on board-level vigilance for arms-length pricing.

Dividends have stepped down ₹3 → ₹3 per share — disciplined through a weak year, but the dividend yield of 1.1% is more about a depressed price than generosity; payout is ~$0.84M against $5.2M PAT. Capital allocation in FY24 was activist — $16.7M for Sudarshan Farm Chemicals plus a 99% stake in Kashmir Chemicals — taken alongside a borrowings spike from $4.5M (FY21) to $76.3M (FY24). The acquisitions look strategically defensible but timing was poor; debt funded growth that arrived just before the channel collapsed.

Skin-in-the-game scorecard

Score: 7/10.

• (+) Founder owns ~48% personally, promoter group 50.44%, no pledge, no insider selling.
• (+) Vimal Kumar acknowledged ownership concentration in transcripts ("I have a major shareholding, my concerns are the same as the company's") — the rhetoric matches the cap table.
• (+) Dividend not cut to zero in a tough year; CAPEX paused rather than financed by promoter dilution at distressed prices.
• (–) Warrant scheme priced at the top of the cycle, payable in tranches, now visibly broken.
• (–) Pay is fixed, performance-link is rhetorical; no clawback in the FY24 scandal year.
• (–) Independent layer is too thin for the founder's voting weight to be meaningfully checked at the board.

4. Board Quality

The structural picture: two independent directors out of six, just at the SEBI minimum for a board chaired by an independent; one of them (Mrs. Chetna) is on six other listed boards and chairs three of this company's five committees, which is more than any single director should carry. Karlekar plugs the agrochem skills hole that the rest of the board lacks but he is non-executive and non-independent. The two executive WTDs (Surendra Sai and Isha Luthra) bring useful operational depth but are dependent on the MD by definition. No qualified financial expert on the audit committee beyond Mrs. Chetna's compliance background — a real gap given the scale of the FY24 sales-return episode.

The committee record is workmanlike: 6 board meetings, 6 audit meetings, 4 NRC, 4 SRC, 3 Risk, 3 CSR, attendance near 100%. No director has been disqualified by MCA. Investor complaints redressed within the year (3 received, 3 closed). Yet the committees did not prevent: (i) the FY24 sales-return write-down that took two years to clean up, (ii) the off-cycle 2-July-2025 director resignations without disclosure of cause, or (iii) the auditor's resignation in August 2025. The form is correct; the substance is unreliable.

5. The Verdict

Grade: C+ (improving from C as Karlekar adds expertise, but capped by board thinness, the unresolved warrant scheme, and concentrated 2025 turnover).

The strongest positives. Promoter alignment is real — 50.44% group ownership, no pledge, no selling, the founder talks to retail investors on every quarterly call and has skin in the game that exceeds every institution combined. Pay is modest. The CAPEX pause in the face of weak operating performance and a broken warrant scheme is the right capital-allocation call. Karlekar's 2025 appointment is a meaningful upgrade to industry expertise. The Audit Chair (Mrs. Chetna) is a competent ICSI-accredited compliance specialist; the form of governance is intact.

The real concerns. (1) Two of three executive directors and the statutory auditor turned over inside a single quarter (Jul–Oct 2025) without public explanation; the company secretary followed. (2) The 2.34 million-share warrant scheme is now ~60% under water and structurally unlikely to convert, leaving the equity dilution it was designed to deliver in limbo and the funding plan it was attached to (CAPEX) on hold. (3) The 2024 sales-return episode (~$33.6M over 9 months) revealed channel-stuffing-adjacent practices that the board did not catch in real time. (4) Independent directors are 2 of 6, and one of them is on six other listed boards. (5) The compensation table is excluded from the public annual report by Section 136(1) carve-out — a legal but minimum-disclosure choice.

One thing that would most likely cause an upgrade. Two crisp signals: (a) the new statutory auditor (appointed October 2025) issuing a clean opinion on FY26 with no emphasis-of-matter on revenue recognition or sales returns; and (b) a third genuinely independent director with operating or audit credentials replacing one of the recent exits. Either alone would matter. Both together would move governance from C+ to B.

One thing that would most likely cause a downgrade. A material disagreement-with-auditor disclosure, a SEBI/SAT inquiry into the FY24 sales-return accounting, or any forced restatement — each would expose that the alignment of interest cannot substitute for independent challenge.